Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women

Ospemifene is a novel selective estrogen receptor modulator (SERM). Here we studied the effects of ospemifene on bone turnover in postmenopausal women. This was a randomized, double-blind study in which 159 healthy postmenopausal women received 30 (n=40), 60 (n=40) or 90 mg (n=40) of ospemifene or p...

Full description

Saved in:
Bibliographic Details
Published in:Gynecological endocrinology 2004-03, Vol.18 (3), p.152-158
Main Authors: Komi, J., Heikkinen, J., Rutanen, M., Halonen, K., Lammintausta, R., Ylikorkala, O.
Format: Article
Language:English
Subjects:
Alkaline Phosphatase - blood
Biomarkers - analysis
Bone Remodeling - drug effects
Bone Turnover
Collagen - urine
Collagen Type I
Double-Blind Method
FC-1271a
Female
Humans
Middle Aged
Ospemifene
Osteoporosis
Peptide Fragments - blood
Peptides - urine
Placebos
Postmenopausal
Postmenopause
Procollagen - blood
Selective Estrogen Receptor Modulators - pharmacology
SERM
Tamoxifen - administration & dosage
Tamoxifen - analogs & derivatives
Tamoxifen - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ospemifene is a novel selective estrogen receptor modulator (SERM). Here we studied the effects of ospemifene on bone turnover in postmenopausal women. This was a randomized, double-blind study in which 159 healthy postmenopausal women received 30 (n=40), 60 (n=40) or 90 mg (n=40) of ospemifene or placebo (n=39) for 3 months. Bone resorption was assessed by measuring the urinary outputs of N- and C-terminal crosslinking telopeptides of type I collagen (NTX and CTX, respectively). Bone formation was assessed by measuring the levels of procollagen type I N propeptide (PINP), procollagen type I C propeptide (PICP), and bone-specific alkaline phosphatase (bone ALP) in serum. All markers were studied at baseline, 3 months, and 2-4 weeks after cessation of the medication. Ospemifene decreased bone resorption dose-dependently, as seen from falls in NTX by 6.1, 9.4 and 12.9% in the 30, 60 and 90 mg ospemifene groups, respectively (p
ISSN:0951-3590
1473-0766
DOI:10.1080/09513590410001672197